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Background: Effective treatments for fibrotic diseases such as idiopathic pulmonary fibrosis are largely lacking.
Transforming growth factor beta (TGFβ) plays a central role in the pathophysiology of fibrosis. We hypothesized
that bone morphogenetic proteins (BMP), another family within the TGFβ superfamily of growth factors, modulate
fibrogenesis driven by TGFβ. We therefore studied the role of endogenous BMP signaling in bleomycin induced
lung fibrosis.
Methods: Lung fibrosis was induced in wild-type or noggin haploinsufficient (Nog+/LacZ) mice by intratracheal
instillation of bleomycin, or phosphate buffered saline as a control. Invasive pulmonary function tests were
performed using the flexiVent® SCIREQ system. The mice were sacrificed and lung tissue was collected for analysis
using histopathology, collagen quantification, immunohistochemistry and gene expression analysis.
Results: Nog+/LacZ mice are a known model of increased BMP signaling and were partially protected from
bleomycin-induced lung fibrosis with reduced Ashcroft score, reduced collagen content and preservation of
pulmonary compliance. In bleomycin-induced lung fibrosis, TGFβ and BMP signaling followed an inverse course,
with dynamic activation of TGFβ signaling and repression of BMP signaling activity.
Conclusions: Upon bleomycin exposure, active BMP signaling is decreased. Derepression of BMP signaling in
Nog+/LacZ mice protects against bleomycin-induced pulmonary fibrosis. Modulating the balance between BMP
and TGFβ, in particular increasing endogenous BMP signals, may therefore be a therapeutic target in fibrotic
lung disease.
Keywords: Transforming growth factor beta, Bone morphogenetic proteins, Bleomycin, Pulmonary fibrosisBackground
Fibrotic diseases, including idiopathic pulmonary fibrosis
(IPF), liver cirrhosis, diabetic nephropathy, arterios-
clerosis, and systemic sclerosis (SSc) are a group of
disorders for which effective therapy is largely lacking.
Fibrosis is characterized by excessive production, depo-
sition, and contraction of extracellular matrix and is
considered an end-stage process responsible for organ
dysfunction and potential organ failure [1]. Pulmonary* Correspondence: rik.lories@uz.kuleuven.be
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post-radiation or chemotherapy, is a major cause of
death and its treatment is considered a major unmet
need [2]. Many open questions remain with regards to
the etiology and pathophysiology of fibrosis. Tissue
fibrosis is generally considered a process of uncontrolled
wound healing. Injury leads to activation, proliferation
and migration of mesenchymal cells. A deregulated and
unrestrained fibroblast compartment produces and de-
posits increased amounts of extracellular matrix (ECM),
resulting in progressive fibrosis of skin and internal or-
gans, leading to architectural damage. Normal wound
healing is regulated by a complex set of interactionstral. This is an Open Access article distributed under the terms of the Creative
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kines and secreted proteins.
TGFβ is considered the major pro-fibrotic cytokine, or-
chestrating fibroblast function as a chemotactic factor [3,4],
and promoting proliferation [5], the deposition of extracel-
lular matrix proteins and fibroblast-to-myofibroblast con-
version [6]. Active TGFβ signaling characterizes both
idiopathic and connective tissue disease-associated lung
fibrosis [7,8]. In rodents, adenoviral overexpression of
TGFβ induces severe lung fibrosis [9,10]. The bone mor-
phogenetic protein (BMP) family also belongs to the TGFβ
superfamily. Originally discovered as molecules that in-
duce ectopic bone formation in vivo [11], BMPs much
alike TGFβs are now considered growth and differenti-
ation factors that play key roles from early development to
postnatal homeostasis, disease and repair of multiple or-
gans, by regulating cell proliferation, lineage specification,
differentiation, cell motility, and death [12]. Increasing
evidence suggests a role for BMP signaling in postnatal
pulmonary fibrotic disease such as idiopathic pulmonary
fibrosis and SSc-related lung fibrosis [13]. The role of
BMP antagonist gremlin has been highlighted, with in-
creased expression in IPF [14] and transient pulmonary
fibrosis in rats resulting from adenoviral gremlin overex-
pression [15]. Anti-fibrotic properties have been attributed
to BMP4 and BMP7 in vitro, antagonizing effects of TGFβ
on lung fibroblasts, suggesting the relevance of the
TGF/BMP interplay and balance [16]. The role of en-
dogenous BMPs in this context remains unknown.
In the BMP/TGFβ signaling cascades ligand-dependent
receptor activation results in phosphorylation of SMAD
family member (SMAD) proteins. Receptor-(R)-SMAD1, −5
and −8 are classically associated with the BMP cascade.
R-SMAD2 and −3 are type I TGFβ receptor substrates,
restricted to TGFβ signaling but TGFβs can also activate
R-SMAD1, −5 and −8 [17]. The common-mediator
SMAD4 (Co-SMAD4) will associate with R-SMADs
upon their phosphorylation and the complex translo-
cates to the nucleus. Transcription is regulated by the
interaction of DNA-binding SMADs with transcrip-
tional co-activators or co-repressors. Inhibitory SMAD6
and SMAD7 (I-SMADs) inhibit BMP and TGFβ signaling
as they bind to the type I receptors, thus interfering with
recruitment and subsequent phosphorylation of R-SMADs.
Furthermore, SMAD6 interferes with the heterodimeriza-
tion of the BMP-associated R-SMADs with SMAD4, ser-
ving as a Co-SMAD decoy for activated SMADs, thereby
more selectively inhibiting BMP signaling [12].
Direct inhibition of growth factor signaling pathways
has not translated well into a clinical setting [18] and
may carry the risk of negatively influencing homeostatic
processes in other tissues and organs. Modulation of en-
dogenous regulators of pro-fibrotic signaling may repre-
sent an alternative approach. Here, we studied the roleof endogenous BMP signaling in lung and skin fibrosis
using bleomycin-induced mouse models of fibrosis
in wild-type (WT) and noggin (Nog) haploinsufficient
(Nog+/LacZ) mice. NOG is a secreted extracellular BMP
antagonist that binds different BMPs thereby interfering
with receptor activation [19]. Nog+/LacZ mice serve as a
model of derepressed BMP signaling [20,21].
In this work, we provide new evidence for a critical
endogenous balance between the related TGFβ and
BMP pathways, determining in vivo fibrotic outcomes in
the lung.
Methods
Animals
Eight-week old male Nog heterozygous mice (Nog+/LacZ)
on a C57BL/6 background (a gift from R. Harland,
Berkeley, CA), weighing 22–25 grams, were used [22,23].
Wild-type (WT) littermates served as controls. Mice were
genotyped by polymerase chain reaction (PCR) genomic
analysis for LacZ [20]. The KU Leuven Ethical Committee
for animal research approved all experiments.
Bleomycin-induced pulmonary fibrosis
Lung fibrosis was induced by intratracheal instillation of
0.05U bleomycin (BLM) (Sanofi-Aventis, Diegem, Belgium),
dissolved in 50 μl of sterile phosphate buffered saline (PBS),
or PBS as a control. An incision was made in the shaved
anterior neck region. Blunt dissection of the salivary
glands and the pretracheal muscles along the midline
exposed the trachea. The animal was placed in 70° upright
position. A 0.3 ml syringe with a 30G needle was placed
between two tracheal cartilaginous rings after which BLM
or PBS was slowly instilled. The wound was closed with
Vicryl 5.0. Pulmonary fibrosis was induced in WT or
Nog+/LacZ mice (WT: BLM n = 28, PBS n = 17; Nog+/LacZ:
BLM n = 14, PBS n = 5). 4 weeks after baseline induction,
invasive pulmonary function tests were performed using the
flexiVent® SCIREQ system (SCIREQ, Montreal, Canada).
Mice were subsequently sacrificed and pulmonary tissue
was collected for histopathology, collagen quantification,
immunohistochemistry and gene expression analysis. For
the timecourse experiment, BLM was administered and
mice were sacrificed 1, 3, 7, 14 and 21 days after
induction.
Pulmonary function tests
Mice were anesthetized with an intraperitoneal injection
of pentobarbital (70 mg/kg) (CEVA, Brussels, Belgium) to
suppress spontaneous breathing. After a tracheostomy, the
mice were connected to the flexiVent system (SCIREQ).
The computer-controlled small animal instrument venti-
lated the mice quasi-sinusoidally with a tidal volume of
10 ml/kg at a frequency of 150 breaths/minute and a posi-
tive end-expiratory pressure of 2 cmH2O to achieve a
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breathing. On the flexiVent we performed a Snapshot per-
turbation. Each time before performing this perturbation,
a total lung capacity perturbation (TLC) was carried out to
normalize the lungs. The data from the TLC perturbation
were not used. The snapshot perturbation was performed
until three acceptable measurements (coefficient of deter-
mination > 0.95) were recorded in each individual subject,
of which an average was calculated. The snapshot perturb-
ation was imposed to measure resistance (R), compliance
(C), and elastance (E) of the whole respiratory system (air-
ways, lung, and chest wall). Only the data of the C are pre-
sented in the results [24].
Histological analysis
After completion of invasive pulmonary function tests,
mice were euthanized with pentobarbital overdose. The
tracheal cannula was removed, the chest cavity was
opened and heart and lungs were removed en bloc. The
left lung was collected for histopathology, inflated with
400 μl of 10% formalin/PBS via the left main bronchus
and fixed in formalin for 24 hours. After paraffin embed-
ding, 5 μm sections were cut throughout the whole lung.
Five sections, with 1 mm interval, were stained with
hematoxylin-eosin (H&E). The semiquantitative Ashcroft
score was used to score pulmonary fibrosis [25]. In short,
upon 100x magnification, each successive field was given a
score ranging from 0 (normal lung) to 8 (total fibrous ob-
literation of the field). All scores from 5 sections were
averaged.
Hydroxyproline assay
The right lung lobes were collected and stored at −80°C
for later analysis. Hydroxyproline quantification was per-
formed as described [26]. Right lung lobes were hydro-
lyzed for 3 hours in 6 M HCl at 120°C. After cooling
down for 15 minutes, pH was neutralized (pH 6–7) with
1 N NaOH. Samples were diluted 1/20 in sterile H20.
Free hydroxyproline was oxidized with Chloramine-T for
20 minutes after which the oxidation reaction was
stopped using 70% perchloric acid. Ehrlich’s reagent was
added and samples heated for 20 minutes in a 60° water
bath. After cooling down for 5 minutes, absorbance was
measured at 570 nm and concentrations were calculated
based on a standard curve.
Immunohistochemistry
For phosphorylated SMAD1/5/8 (pSMAD1/5/8) immuno-
histochemistry, sections were quenched with 3% H2O2/
H2O. Antigen retrieval was performed in a 10 mM sodium
citrate buffer and sections were preincubated with donkey
serum (20% in Tris buffered saline (TBS)). Sections were
incubated overnight at 4°C with primary antibody against
pSMAD1/5/8 (1:50 dilution; Cell Signaling, Leiden, TheNetherlands). Negative control studies were performed
with species-specific IgG (Jackson ImmunoResearch,
Te Huissen, The Netherlands). Secondary antibodies
were horseradish peroxidase (HRP)–conjugated antibodies
(1:200 dilution; Jackson ImmunoResearch, Te Huissen, The
Netherlands). For proliferating cell nuclear antigen (PCNA)
immunohistochemistry, sections were quenched with 3%
H2O2/H2O. Antigen retrieval was performed in a 10 mM
sodium citrate buffer and sections were preincubated with
goat serum (20% in Phosphate buffered saline (PBS)-
Tween). Sections were incubated overnight at 4°C with
primary antibody against PCNA (1:500 dilution; Abcam
ab2426, Cambridge, United Kingdom). Negative control
studies were performed with IgG and PBS. Secondary
antibodies were horseradish peroxidase (HRP)–conjugated
antibodies (1:100 dilution; Jackson ImmunoResearch,
Te Huissen, The Netherlands). TUNEL stainings were
performed using the In Situ Cell Death Detection kit, TMR
Red according to the protocol (Roche, Vilvoorde, Belgium).
Western blot analysis
Lung tissues were homogenized in 200 μl Cell Extraction
Buffer (Life Technologies, Gent, Belgium) supplemented
with 5% Proteinase Inhibitor Cocktail (Sigma Aldrich,
Diegem, Belgium) and 1 mM phenylmethylsulfonyl fluo-
ride (PMSF) (Sigma Aldrich, Diegem, Belgium). 5 μg of
protein were loaded onto a 4–12% Bis-Tris gel (Life
Technologies, Gent, Belgium). Electrophoresis was carried
out in running buffer (NuPAGE MOPS SDS running buf-
fer (20×); Life Technologies, Gent, Belgium) at 200 V for
30 minutes. Proteins were transferred onto a polyvi-
nylidene difluoride membrane using semi-dry transfer
(Bio-Rad, Temse, Belgium) for 60 minutes. Nonspecific
binding sites were blocked for 1 hour with 5% skimmed
milk powder in TBS–Tween (TBST). Blots were probed
with rabbit antiserum against total and phosphorylated
forms of SMAD1/5/8 or SMAD2/3 (dilution 1/1000 in 5%
Bovine Serum Albumin (BSA)) overnight at 4°C. Next day,
the membrane was incubated with a HRP–conjugated
goat anti-rabbit secondary antibody (dilution 1/5000 in
5% skimmed milk powder in TBST) (Jackson Immuno-
Research, Te Huissen, The Netherlands) for 1 hour. All
washes were performed with TBST (3 × 10 minutes).
RNA isolation and quantitative reverse
transcription-polymerase chain reaction
Total RNA was extracted from lung homogenates using
NucleoSpin RNA isolation kit (Machery Nagel, Eupen,
Belgium) and reverse-transcribed using First strand cDNA
synthesis kit (Fermentas, St. Leon-Rot, Germany). Gene ex-
pression levels were quantified using Taqman Assays-on-
Demand (Life Technologies, Gent, Belgium). Expression
was normalized to hypoxanthine-guanine phosphoribosyl-
transferase (Hprt) and subsequently normalized to the
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method (ΔΔCT).
Statistics
Data were analyzed using GraphPad Prism 6.0 (www.
graphpad.com). For the in vivo experiments and ex vivo
analyses, two-way ANOVA was used after rank transform-
ation to control for differences in variance. Results are re-
ported for main effects (genotype, BLM vs. PBS) and for
interaction. For two-group comparisons unpaired t-tests ap-
plying Welch correction for unequal variances when neces-
sary were used. P-values < 0.05 were considered significant.
Results
Noggin haploinsufficiency protects mice from lung fibrosis
Nog+/LacZ mice were previously established as a model of
enhanced BMP signaling [20,21,27]. The lungs of theseFigure 1 Noggin haploinsufficiency protects mice from bleomycin-ind
Nog+/LacZ mice, 4 weeks after PBS or bleomycin instillation. (Hematoxylin-Eosin
BLM n = 25) and Nog+/LacZ mice (PBS n = 5, BLM n = 14), 4 weeks after bleomy
(PBS n = 5, BLM n = 5) and Nog+/LacZ mice (PBS n = 3, BLM n = 8), 4 weeks
(PBS n = 12, BLM n = 16) and Nog+/LacZ mice (PBS n = 7, BLM n = 10), 4 weeks
post 2-way ANOVA; data presented as mean and SEM).mice appeared healthy with normal lung histology
(Figure 1A) and compliance (0.0412 +/− 0.0016 ml/cm
H2O (mean & SEM) in wild-type (WT) versus
0.0406 +/− 0.0008 ml/cm H2O (mean & SEM) in
Nog+/LacZ mice). In the bleomycin-induced model,
Nog+/LacZ mice were partially protected from lung fibrosis
compared to WT mice (Figure 1A). Histopathological
Ashcroft score was significantly different as indicated by
2-way ANOVA analysis (p = 0.0203 for interaction bet-
ween genotype and bleomycin treatment, p < 0.0001 for
main effect bleomycin and p = 0.794 for main effect geno-
type) (Figure 1B). Similarly Nog+/LacZ mice had lower col-
lagen content (Figure 1C) (p = 0.9 for interaction between
genotype and bleomycin treatment, p < 0.0001 for main
effect bleomycin and p = 0.013 for main effect genotype).
Pulmonary compliance was significantly different as indi-
cated by 2-factor analysis (p = 0.0431 for interactionuced lung fibrosis. (A) Representative images of lungs from WT and
staining; bar = 200 μm) (B) Ashcroft score from WT mice (PBS n = 20,
cin instillation. (C) Hydroxyproline content of right lungs from WT mice
after bleomycin instillation. (D) Pulmonary compliance of WT mice
after bleomycin instillation. (*p < 0.05 by Sidak multiple comparison test
Figure 2 Dynamics of TGFβ and BMP signaling of wild-type
mice in bleomycin-induced lung fibrosis. (A) Gene expression
level of TGFβ1, Collagen1α2, Bmp2, Bmp4, Bmp6 and Bmp7 (n = 5 at
day 0, n = 4 at day 7 and 14, n = 2 at day 21, data are mean and
SEM of ΔΔCT values normalized to control conditions and Hprt).
(B) Gene expression level of noggin (n = 3 at day 0 and day 1, n = 4
at day 7 and 14, n = 2 at day 21, data are mean and SEM of ΔΔCT
values normalized to control conditions and Hprt). (C) Western blot
of representative lung protein extracts from mice 1, 3, 7, 14 and
21 days after bleomycin instillation, labeled with antibodies against
pSMAD3, pSMAD1/5/8 and GAPDH.
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for main effect bleomycin and p = 0.283 for main effect
genotype) (Figure 1D).
TGFβ and BMP signaling show inversed dynamics in the
bleomycin lung fibrosis model
Gene expression analysis showed dynamic changes in
TGFβ/BMP signaling in the course of bleomycin-induced
lung fibrosis. Tgfβ1 mRNA is transiently upregulated at day
7 and 14 after bleomycin instillation (Figure 2A), paralleling
expression of Coll1α2 (Figure 2A), returning to base-
line levels by day 21. In contrast, expression levels of
Bmp2, −4, −6 but not Bmp7 were downregulated over the
course of the model (Figure 2A). Nog expression was de-
tected in the lung, and was upregulated early after bleo-
mycin instillation, peaking at day 3 (Figure 2B). Western
Blot analysis confirmed the downstream effect of downre-
gulated BMP ligands and upregulated BMP antagonist nog-
gin, showing decreased pSMAD1/5/8 levels while the TGFβ
pathway showed an inverse activated course, reflected by
transient increased in pSMAD3 (day 7–14) (Figure 2C).
Immunohistochemistry further supported this dynamic
decrease in phosphorylation of SMAD1/5/8 during the
course of the model. PSMAD1/5/8 signal was high in
bronchial epithelial cells in healthy 8-week old mice
(Figure 3). No positive cells were identified in more distal
airways, alveoli or blood vessels. Upon bleomycin chal-
lenge, the number and intensity of pSMAD1/5/8 positive
cells was reduced by day 7, resulting in only scattered,
faint staining in bronchial epithelial cells, with almost
absent nuclear staining. The number of pSMAD1/5/8
positive cells remained low 14 days after bleomycin instil-
lation, and slowly recovered by day 21.
The changes in the BMP signaling pathway listed above
were attenuated in Nog+/LacZ mice. Levels of pSMAD1/5/8
and pSMAD3 appeared unaffected when compared to
PBS treatment (Figure 4A). Levels of pSMAD1/5/8 in-
versely correlated with activation of ERK, a mitogen acti-
vated protein kinase associated with progression of lung
fibrosis [28]. Immunohistochemistry confirmed the sus-
tained activity of the BMP signal after bleomycin in-
stillation, reflected by the persistence of pSMAD1/5/8
positivity in bronchial epithelial cells in Nog+/LacZ mice,
14 days after bleomycin instillation (Figure 4B). Further-
more, in Nog+/LacZ mice Bmp2, −4 and −6 levels were
higher than in WT mice (Figure 5A). In addition, expres-
sion levels of inhibitory SMADs were enhanced as com-
pared to WT mice suggesting homeostatic regulation of
TGFβ signaling (Figure 5B).
Evidence for reduced apoptosis and reduced proliferation
in Nog+/LacZ mice after bleomycin instillation
We evaluated proliferation and apoptosis in WT and
Nog+/LacZ mice, 4 weeks after bleomycin instillation. Weobserved higher numbers of PCNA positive cells in WT
mice compared to Nog+/LacZ mice (Figure 6A). This was
most evident in bronchial epithelial cells. We assessed
apoptosis using TUNEL staining and demonstrate that
apoptosis is seen both in bronchial and alveolar cells
in WT mice, but is largely absent in Nog+/LacZ mice
(Figure 6B).
Figure 3 Dynamics of TGFβ and BMP signaling of wild-type mice in bleomycin-induced lung fibrosis. pSMAD1/5/8 immunohistochemistry
at different time points in the bleomycin model in WT mice. (bars are 500 μm and 125 μm respectively).
Figure 4 Dynamics of TGFβ and BMP signaling of Nog+/LacZ mice in bleomycin-induced lung fibrosis. (A) Western blot of representative
lung protein extracts from WT and Nog+/LacZ mice, 4 weeks after treatment with bleomycin or PBS, labeled with antibodies against pSMAD3,
pSMAD1/5/8, ERK and pERK. (B) pSMAD1/5/8 immunohistochemistry at different time points in PBS or bleomycin treated WT or Nog+/LacZ
mice (bar = 150 μm).
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Figure 5 Dynamics of TGFβ and BMP signaling of Nog+/LacZ
mice in bleomycin-induced lung fibrosis. (A) Gene expression
level of Bmp’s in WT and Nog+/LacZ mice, 4 weeks after treatment
with bleomycin (n = 6-10 per group; data presented as mean and
SEM). (B) Gene expression level of Smad6 and Smad7 in WT and
Nog+/LacZ mice, 4 weeks after treatment with bleomycin (*p < 0.05;
n = 5 per group; data presented as mean and SEM values normalized
to control conditions and Hprt).
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Fibrotic diseases, like systemic sclerosis-associated lung
fibrosis and idiopathic pulmonary fibrosis are severe
diseases with high morbidity and mortality. TGFβ super-
family members are crucial in lung development. In-
creasing evidence supports an additional role for these
pathways in postnatal homeostasis and disease as they
regulate mesenchymal proliferation, myofibroblast diffe-
rentiation, extracellular matrix production and fibrotic
disease progression [29,30]. Here we show that changes
in endogenous BMP signaling in noggin haploinsuf-
ficient mice reduce lung fibrosis in the bleomycin-
induced model, suggesting that BMPs are homeostatic
signals in the lung.
The noggin haploinsufficient mouse is a genetic model
that results in de-repression of BMP signaling andhighlights the impact of discrete shifts in BMP signaling
due to the partial absence of the broad-spectrum endo-
genous antagonist noggin (about 50% reduction in expres-
sion). Nog+/LacZ mice show a discrete skeletal phenotype
with fusion of tarsal joints depending on the background
strain [21], are partially protected against cartilage damage
in models of osteoarthritis [20] and have conductive hear-
ing loss [27]. We detected no differences as compared to
wild-type animals in general histology of the lungs and in
pulmonary function tests. Upon challenge with bleomycin,
progression of fibrosis in the lungs was significantly re-
duced. Although we detected Nog expression in the mouse
lung, increased systemic Noggin levels likely contribute to
these effects as suggested earlier in arthritis models in this
specific transgenic mouse strain [20].
The anti-fibrotic properties of exogenous BMPs have
been investigated in different cells and organs. In a mouse
model of pancreatic fibrosis, BMP signaling plays a pro-
tective role [31]. BMP2 antagonizes renal fibrosis in the
rat ureter obstruction model in vivo [32] and promotes
the catabolism of the type I TGFβ receptor in renal fibro-
blasts. In lung fibroblasts, BMP2 inhibits fibroblast-
to-myofibroblast transdifferentiation in vitro through
PKC-mediated inhibition of endothelin-dependent fibro-
blast chloride currents [33]. BMP4 and BMP7 attenuate
TGFβ-induced activation of normal human lung fibro-
blasts, reducing proliferation, differentiation, collagen ex-
pression and the activity of proMMP1 and proMMP2
[16]. BMP7 opposes TGFβ1-mediated collagen induction
in mouse pulmonary myofibroblasts [34] and inhibits
silica-induced lung fibrosis in rats [35]. Interfering with
BMP signaling appears to affect postnatal lung homeosta-
sis. Tilorone, a BMP inducer, has been shown to have anti-
fibrotic effects in a mouse model of silica-induced lung
fibrosis [36]. Overexpression of the BMP antagonist grem-
lin results in transient fibrosis [15] associated with in-
creased apoptosis, hyperplasia and proliferation of type I
and type II pneumocytes and increased proliferation of
fibroblasts. In IPF, the BMP antagonist gremlin was
consistently shown to be upregulated and localized in
mesenchymal cells [14]. These findings were elaborated in
asbestos-induced murine lung fibrosis [37], with TGFβ
type I receptor-dependent upregulation of gremlin expres-
sion at day 14 with interstitial localization. Consistent with
our observations, a positive pSMAD1/5/8 signal was ob-
served in bronchial epithelial cells of controls but was
almost undetectable in asbestos-exposed epithelial cells.
Using a BMP reporter mouse, Sountoulidis et al. demon-
strate that BMP signaling is increased in alveolar epithelial
cells following bleomycin injury and that this increase co-
incides with an enrichment of alveolar progenitor cells
[30]. In our work, we demonstrate clear dynamic changes
in the activity of the BMP signaling pathways in bronchial
epithelial cells, in concordance with the findings of
Figure 6 Evidence for reduced apoptosis and reduced proliferation in Nog+/LacZ mice after bleomycin instillation. (A) PCNA immunohistochemistry
in WT and Nog+/LacZ mice, 4 weeks after treatment with bleomycin. (B) TUNEL in WT and Nog+/LacZ mice, 4 weeks after treatment with bleomycin.
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positive alveolar epithelial cells. Furthermore, we detect a
downregulation of Bmp2, 4 and 6 expression. It cannot be
ruled out that this apparent paradox between our work
and the work by Sountoulidis et al. results from methodo-
logical or intrinisic differences between the models. Smad
phosphorylation is a rapid and short-lived event upon ex-
posure to BMP signaling. Therefore the reporter approach
with BMP responsive element driven gene expression may
be more sensitive to document the range of BMP signal-
ing. In contrast, immunohistochemistry may highlight the
most dynamically regulated sites; in this case the bronchial
epithelial cells. Sountoulidis et al. induce lung fibrosis in
mice that are of older age, and use significantly lower
bleomycin doses. Furthermore, it is known that TGFβ is
able to result in phosphorylation of SMAD1/5/8 through
Alk1, resulting in non-BMP driven activation of down-
stream pSMAD1/5/8 signaling [38–40].TGFβ and BMP signaling are crucial in the epithelial-
mesenchymal interactions [41] in lung morphogenesis
that regulate branching, cell fate, proliferation and death
of both mesenchymal and endodermal cells [42,43]. In
our work, we evaluated cell fate after bleomycin instilla-
tion in WT and Nog+/LacZ mice. We show that WT mice
have more apoptosis in bronchial and alveolar epithelial
cells and increased proliferation in bronchial epithelial
cells, when compared to Nog+/LacZ mice. We hypothesize
that Noggin haploinsufficiency and increased BMP sig-
naling activity results in less tissue remodeling with re-
duced cell proliferation and cell death.
Based on our data, we hypothesize that in healthy
lungs, BMPs play a role in normal epithelial home-
ostasis. Upon bleomycin exposure, the integrity of the
bronchial epithelial cells is threatened, with repression
of the BMPs. The reduced availability of BMP ligands re-
sults in decreased BMP signaling activity and decreased
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chymal compartment.
Conclusions
Alteration of the TGFβ/BMP balance in vivo, demon-
strated in the Nog+/LacZ mice, effectively alters fibrotic out-
comes, demonstrating the biological relevance of these
findings. The balance between BMPs and TGFβs may
have therapeutic potential with BMP signaling potentia-
ting drugs currently under research. The data presented
here therefore could contribute towards more focus on
endogenous and exogenous BMP modulators as potential
therapeutics for these devastating fibrotic diseases.
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